Results 151 to 160 of about 19,748 (182)

Free Light Chains of Immunoglobulins in Amyloidosis

Acta Medica Scandinavica, 1979
ABSTRACT Monomeric (M) and dimeric (D) forms of free light chains in serum have been measured by a sensitive radioimmunoassay in eight patients with amyloidosis without monoclonal proteins. Significantly elevated concentrations of D lambda chains were demonstrated in two of four patients with localized amyloidosis.
J, Sølling, K, Sølling
openaire   +2 more sources

Systemic Immunoglobulin Light-Chain Amyloidosis

Clinical Lymphoma and Myeloma, 2006
Amyloidosis is a rare disease in which amyloid fibrils compromise organ function and lead to death. Systemic immunoglobulin light-chain amyloidosis, usually caused by free light chains (FLCs) made by clonal plasma cells, is the most frequent type. Hereditary and senile systemic amyloidosis are less frequent types.
openaire   +2 more sources

Managing Systemic Light-Chain Amyloidosis

Journal of the National Comprehensive Cancer Network, 2007
Amyloidosis is a rare disease in which a specific protein is deposited as aggregated interstitial fibrils that can compromise organ function and lead to death. Immunoglobulin (Ig) light-chain amyloidosis (AL), caused by the monoclonal gammopathy of a plasma cell dyscrasia, is the most common type.
openaire   +2 more sources

Immunoglobulin Light Chain and Systemic Light-Chain Amyloidosis

2007
Light-chain amyloidosis (AL) is characterized by the clonal expansion of plasma B cells that secrete large amounts of monoclonal immunoglobulin light chains. The free light chains circulate in serum and form amyloid fibrils on vital organs such as the kidney, heart, and liver causing organ failure and eventually death.
Marina Ramirez-Alvarado, Janelle K. De Stigter, Elizabeth M. Baden, Laura A. Sikkink, Richard W. McLaughlin, Anya L. Taboas   +5 more
openaire   +1 more source

Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis

Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021
Jelger Louwsma, Johan Bijzet, Wilfried W H Roeloffzen   +2 more
exaly  

[Amyloid light chain amyloidosis].

Brain and nerve = Shinkei kenkyu no shinpo, 2014
Primary amyloid light chain (AL) amyloidosis is the most common and most aggressive form of systemic amyloidosis. In AL amyloidosis, the products of free light chains (FLCs) of monoclonal amyloidogenic plasma cells deposit in the heart, kidneys, liver, gastrointestinal tract, autonomic nerve systems, and soft tissues, consequently leading to ...
Kenshi, Suzuki, Toshiko, Shimizu
openaire   +1 more source

The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement

Annals of Medicine, 2022
Guisheng Ren, Xianghua Huang
exaly  

Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy

JACC: Cardiovascular Imaging, 2022
Sarah A M Cuddy, Michael Jerosch-Herold, Rodney H Falk   +2 more
exaly  

Useful polyclonal antibodies against synthetic peptides corresponding to immunoglobulin light chain constant region for immunohistochemical detection of immunoglobulin light chain amyloidosis

Pathology International, 2001
Yoshinobu Hoshii, Mihoko Setoguchi, Junkô Ueda   +2 more
exaly  

Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis

Mayo Clinic Proceedings, 2017
Taxiarchis Kourelis, Robert A Kyle, David Dingli   +2 more
exaly